Evidence map›Paper›PMID 24458973›Full record

ArticleChembiochem : a European journal of chemical biology2014

3-substituted indazoles as configurationally locked 4EGI-1 mimetics and inhibitors of the eIF4E/eIF4G interaction.

Revital Yefidoff-Freedman, Ting Chen, Rupam Sahoo, Limo Chen, Gerhard Wagner, Jose A Halperin, Bertal H Aktas, Michael Chorev

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Signalling to eIF4E in cancer.Biochemical Society transactions · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Revital Yefidoff-FreedmanLaboratory for Translational Research, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115 (USA); Hematology Laboratory for Translational Research, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 7, Boston, MA 02115 (USA).
Ting Chen
Rupam Sahoo
Limo Chen
Gerhard Wagner
Jose A Halperin
Bertal H Aktas
Michael Chorev
Harvard University · USBrigham and Women's Hospital · US

Funding

STRUCTURAL BASIS OF TRANSLATION INITIATION BY EIF-4ER01CA068262 · NCI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WAGNER, GERHARD · 1996 to 2015
$3.6M
Development of Translation Initiation Inhibitors and their Anti-Cancer ActivityR01CA121357 · NCI · HARVARD MEDICAL SCHOOL · PI CHOREV, MICHAEL · 2008 to 2012
$1.7M
NCI NIH HHS R01 CA068262NCI NIH HHS R01 CA121357NCI NIH HHS R01CA121357
6 · The paper itself

Abstract

4EGI-1, the prototypic inhibitor of eIF4E/eIF4G interaction, was identified in a high-throughput screening of small-molecule libraries with the aid of a fluorescence polarization assay that measures inhibition of binding of an eIF4G-derived peptide to recombinant eIF4E. As such, the molecular probe 4EGI-1 has potential for the study of molecular mechanisms involved in human disorders characterized by loss of physiological restraints on translation initiation. A hit-to-lead optimization campaign was carried out to overcome the configurational instability in 4EGI-1, which stems from the E-to-Z isomerization of the hydrazone function. We identified compound 1 a, in which the labile hydrazone was incorporated into a rigid indazole scaffold, as a promising rigidified 4EGI-1 mimetic lead. In a structure-activity relationship study directed towards probing the structural latitude of this new chemotype as an inhibitor of eIF4E/eIF4G interaction and translation initiation we identified 1 d, an indazole-based 4EGI-1 mimetic, as a new and improved lead inhibitor of eIF4E/eIF4G interaction and a promising molecular probe candidate for elucidation of the role of cap-dependent translation initiation in a host of pathophysiological states.

Indexed as

Cell Line, TumorCell ProliferationEukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GHumansHydrazonesIndazolesProtein BindingProtein Interaction Domains and MotifsStereoisomerismStructure-Activity RelationshipThiazoles4EGI-1 compoundEukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GHydrazonesIndazolesThiazoleseIF4E/eIF4G interactioninhibitorsmolecular probesprotein-protein interactionstranslation initiation

Identifiers

PMID24458973
PMCPMC4259117
OpenAlexW1966631935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.